Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Maelicke A

Laboratory of Molecular Neurobiology, Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University Medical School, Mainz, Germany. alfred.maelicke@uni-mainz.de

Dement Geriatr Cogn Disord 2000 Sep;11 Suppl 1:11-8

Abstract

Impairment of the central cholinergic system has a pivotal role in the cognitive decline observed in patients with Alzheimer's disease (AD).  One of the most prominent cholinergic deficits is the reduced number of nicotinic acetylcholine receptors (nAChR) in the brain.  Since these receptors are important for memory and learning, enhancing nicotinic neurotransmission is a promising treatment strategy for AD.  The two most common approaches to correcting these cholinergic deficits are to increase the synaptic availability of acetylcholine (ACh) by inhibiting acetylcholinesterase (AChE), or to mimic the effects of ACh (nicotinic agonists) by acting directly on nicotinic receptors. Clinical studies suggest that AChE inhibitors produce only short-term symptomatic improvement.  Similarly, long-term use of nicotinic agonists may induce desensitization of nicotinic receptors, leading to tolerance and therefore limiting the duration of efficacy.  Allosteric modulation of nAChR is a novel approach, which circumvents the development of tolerance.  Allosteric modulators bind to a site on nAChR that is different to the binding site of the natural agonist, ACh.  This allosteric interaction amplifies the actions of ACh at post- and presynaptic nAChR. In particular, presynaptic nAChR are capable of modulating the release of ACh and other neurotransmitters, such as glutamate, serotonin and GABA, which may contribute to symptoms of the illness.  Allosteric modulation of nAChR could therefore produce significant therapeutic benefit in AD. One of the most potent of these allosteric modulators is galantamine.  As well as modulating nAChR, galantamine inhib- its AChE.  The extent to which the clinical benefits of galantamine are attributable specifically to its nicotinic effects is uncertain and requires further investigation.  However, galantamine maintains patients' level of cognitive and daily function for at least 1 year, which has not been reported for other AChE inhibitors.  Galantamine's modulatory effects on nAChR may influence transcriptional regulation, resulting in an increased synthesis of nAChR.  This may account for galantamine's sustained efficacy.

BACK                                                 to order

Research abstracts
  Galantamine: its use in Alzheimer's
  Galantamine: in Alzheimer's patients
  Galantamine:
acetylcholinesterase inhibition
  Galantamine: therapeutic effects beyond cognition
  Galantamine: benefits to Alzheimer's patients
 
Galantamine: nicotinic receptors in Alzheimer's
  Galantamine: a study in Alzheimer's  
  Galantamine: its effects on Alzheimer's  
  Galantamine: a new treatment for Alzheimer's
  Galantamine: effect on nicotinic receptor binding
  Galantamine: an allosterically potentiating ligand
  Galantamine: nicotinic modulation in an animal model
  Galantamine: memory & nicotinic receptors in rats  
  Galantamine: a 6 month study:

 

www.AlzheimersTreatments.com